NCT06882174View on ClinicalTrials.gov

This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 6, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
DRUG

Scheduling of the time of pembrolizumab infusions

The intervention in this study is scheduling of the time of pembrolizumab infusions.

All Listed Sponsors
lead

AHS Cancer Control Alberta

OTHER